6/9/25 We are currently making changes to reflect the new Health Sciences Division structure. Thank you for your patience while we make the transition.

Sign in
Back
A Randomized Trial of Nafamostat for Covid-19
Journal article   Peer reviewed

A Randomized Trial of Nafamostat for Covid-19

Susan C Morpeth, Balasubramanian Venkatesh, James A Totterdell, Grace M McPhee, Robert K Mahar, Mark Jones, Methma Bandara, Lauren A Barina, Bhupendra K Basnet, Asha C Bowen, …
NEJM evidence, Vol.2(11), pp.EVIDoa2300132-EVIDoa2300132
11/2023
DOI: https://doi.org/10.1056/EVIDoa2300132
Handle:
https://hdl.handle.net/10523/18908

Abstract

Benzamidines COVID-19 Guanidines - pharmacology Humans SARS-CoV-2
A Randomized Trial of Nafamostat for Covid-19Nafamostat mesylate is a potent in vitro antiviral that inhibits the host transmembrane protease serine 2 enzyme used by SARS-CoV-2 for cell entry. Morpeth et al report the results of an open-label randomized clinical trial of nafamostat for noncritically ill patients with Covid-19.

Metrics

16 Record Views

Details

Logo image